Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Ascentis Independent Advisors Buys 2,294 Shares of Cencora, Inc. $COR

AI-generated analysis

πŸ“‰ Cencora reported Q1 EPS of $4.75, missing analyst consensus estimates of $4.82 by $0.07.

πŸ’° Quarterly revenue reached $78.36 billion, up 3.9% year-over-year against a consensus of $81.09 billion.

πŸ“ˆ Ascentis Independent Advisors raised its stake in Cencora by 109.0% to own 4,399 shares worth $1.382 million.

🏦 Multiple hedge funds including Kemnay Advisory Services and Oakworth Capital Inc. established new positions in the fourth quarter.

πŸ“Š The stock carries a market cap of $58.13 billion with a PEG ratio of 1.65 and a beta of 0.58.

🎯 Analyst consensus rating is 'Moderate Buy' with an average target price of $367.75 based on MarketBeat data.

πŸ“ˆ UBS Group increased its price objective to $412.00 and reaffirmed a 'buy' rating for the stock.

πŸ“‰ Wells Fargo & Company cut its price objective to $331.00 but maintained an 'overweight' rating.

πŸ’Έ The company announced a new $2.00 billion share buyback plan approved by the Board of Directors.

πŸ’° A quarterly dividend of $0.60 per share was paid on June 1st with an annualized yield of 0.8%.

πŸ“‰ The stock currently trades above its 50-day moving average but below its 200-day moving average.

🏒 Cencora operates as a global healthcare services and pharmaceutical distribution company with a market cap of $58.13 billion.

Bullish Signals
  • Cencora generated revenue of $78.36 billion, achieving a 3.9% year-over-year growth rate.
  • The company maintains a high return on equity of 135.20%, indicating strong capital efficiency.
  • Ascentis Independent Advisors significantly increased its position by 109.0%, signaling institutional confidence.
  • UBS Group raised its price target to $412.00 and issued a 'buy' rating on the stock.
  • The Board of Directors approved a substantial $2.00 billion share buyback plan, suggesting management views shares as undervalued.
  • Analyst consensus remains positive with an average target price of $367.75 and a 'Moderate Buy' rating.
Risk Factors
  • Cencora missed quarterly earnings expectations by $0.07 per share, reporting $4.75 EPS versus the $4.82 consensus.
  • Wells Fargo & Company lowered its price objective from $429.00 to $331.00, reflecting some analyst caution.
  • The stock currently trades below its 200-day simple moving average of $319.86, indicating potential short-term weakness.
  • Revenue of $78.36 billion came in below the consensus estimate of $81.09 billion for the quarter.
Full Analysis
Cencora, Inc. (NYSE:COR) recently reported its quarterly earnings, posting $4.75 per share in EPS against a consensus estimate of $4.82, resulting in a miss of $0.07. The company generated revenue of $78.36 billion for the quarter, representing a 3.9% year-over-year increase compared to the estimated $81.09 billion. Despite missing earnings expectations, the firm maintains a strong return on equity of 135.20% and has set full-year 2026 guidance between $17.65 and $17.90 per share. Institutional interest in Cencora remains active with several hedge funds adjusting their positions. Ascentis Independent Advisors increased its stake by 109.0% to own 4,399 shares valued at $1.382 million. Other notable activity includes Kemnay Advisory Services, Oakworth Capital Inc., and Elyxium Wealth LLC establishing new stakes in the fourth quarter, while Archer Investment Corp lifted its position significantly. Analyst sentiment is mixed with a consensus 'Moderate Buy' rating and an average target price of $367.75. UBS Group raised its price objective to $412.00 with a 'buy' rating, whereas Wells Fargo & Company lowered its target to $331.00 while maintaining an 'overweight' rating. The company also announced a new $2.00 billion share buyback plan approved by the Board of Directors and paid a quarterly dividend of $0.60 per share.